TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01013870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
Study: NCT01235273

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard placebo
Study: NCT01982344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-exchange-room
Study: NCT03132714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: Administration of Amoxicillin 500mg tid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: Administration of Amoxicillin 500mg tid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: Administration of Amoxicillin 500mg tid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400mg
Description: Administration of Metronidazole 400mg tid for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400mg
Description: Administration of Metronidazole 400mg tid for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400mg
Description: Administration of Metronidazole 400mg tid for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Administration of Clarithromycin 500mg bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Administration of Clarithromycin 500mg bid for 7 days
Study: NCT03127202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)
Description: Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
Study: NCT02945761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High concentration of sugar solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgical dressing change
Study: NCT02948777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Study: NCT01013870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
Study: NCT04987450

Intervention type: DRUG
Intervention: Methylprednisolone, prednisone
Description: The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
Study: NCT06044753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap.
Study: NCT03993353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 10 mg by mouth daily
Study: NCT03799003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)
Study: NCT03132714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Administration of Clarithromycin 500mg bid for 7 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single application of PDT
Description: Single application of photodynamic therapy (PDT) at day 0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single application of PDT
Description: Single application of photodynamic therapy (PDT) at day 0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated application of PDT
Description: Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated application of PDT
Description: Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
Study: NCT03311854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
Study: NCT00310713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Description: Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
Study: NCT03330132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
Description: 0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (NH formulation)
Description: 0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (NH formulation)
Description: 0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (NH formulation)
Description: 0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (NH formulation)
Description: 0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose inactivated influenza vaccine (NH formulation)
Description: 0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Description: 0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
Description: 0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
Study: NCT04146090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-pressure pneumoperitoneum
Description: Pneumoperitoneum will be maintained in 10 mmHg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard pressure pneumoperitoneum
Description: Pneumoperitoneum will be maintained in 14 mmHg
Study: NCT00562718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02956681

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention Group
Description: This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
Study: NCT01682421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weak steroid (Flurolon, Allergan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potent steroid (Maxidex, Alcon)
Study: NCT02528019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibiotors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT04383249

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology result
Description: Pathology result of the hernia sac
Study: NCT03019016

Intervention type: PROCEDURE
Intervention: Right Colectomy
Description: Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.

Intervention type: PROCEDURE
Intervention: Right Colectomy
Description: Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.

Intervention type: PROCEDURE
Intervention: Right Colectomy
Description: Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.

Intervention type: PROCEDURE
Intervention: Right Colectomy
Description: Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
Study: NCT03799003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1951
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenously (IV)
Study: NCT02114632

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eye Q
Description: 3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
Study: NCT00416351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Study: NCT03247907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition A: CPAP with No Humidification
Description: CPAP with No Humidification with no mouth leak

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition B: CPAP with No Humidification
Description: CPAP with No Humidification with mouth leak

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition C: CPAP with Cold Passover
Description: CPAP with Cold Passover with mouth leak

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition D: CPAP with Modified humidifier
Description: CPAP with Modified humidifier with mouth leak

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition E: CPAP with Ambient Tracking
Description: CPAP with Ambient Tracking with mouth leak

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition F: CPAP with Heated Humidification
Description: CPAP with Heated Humidification at default setting with mouth leak
Study: NCT03081897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRANC Block group
Description: General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPRANC Control group
Description: General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
Study: NCT03417427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine and Ara-C
Description: Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ara-C
Description: Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
Study: NCT03247907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition G: CPAP with Heated Humidification
Description: CPAP with Heated Humidification at max setting with mouth leak
Study: NCT04572269

Intervention type: OTHER
Intervention: No Intervention
Description: This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
Study: NCT01897896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Study: NCT01265147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 40mg/m2/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 40mg/m2/w
Study: NCT02107196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant 10 mg
Description: Oral tablet, to be given once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
Study: NCT00716625

Intervention type: DRUG
Intervention: sunitinib malate
Description: SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition.
Study: NCT04244643

Intervention type: OTHER
Intervention: data collection
Description: Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height
Study: NCT01131091

Intervention type: DRUG
Group type: OTHER
Intervention: SK-0403
Description: SK-0403 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: SK-0403
Description: SK-0403 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: SK-0403
Description: SK-0403 400 mg

Intervention type: DRUG
Group type: OTHER
Intervention: SK-0403
Description: SK-0403 400 mg
Study: NCT00645138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered.
Study: NCT03247907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condition H: CPAP with New level humidification
Description: CPAP with New level humidification with mouth leak
Study: NCT01131091

Intervention type: DRUG
Group type: OTHER
Intervention: SK-0403
Description: SK-0403 400 mg
Study: NCT00645138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.